Amphastar Pharmaceuticals, Inc.

AMPH · Nasdaq · United States

Share price · AMPH

$29.71+8.37 (+39.22%) 3M

close as of 2026-11-18 · 24h delayed · vol 526K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AMPH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Sep 2026+4.8%

    Nothing announced by AMPH that day or the session before.

  2. 24 Sep 2026+5.2%
  3. 8 May 2026-20.9%
  4. 27 Feb 2026-23.6%
  5. 26 Feb 2026-5.3%
  6. 23 Feb 2026-3.4%
  7. 2 Feb 2026+5.4%

    Nothing announced by AMPH that day or the session before.

  8. 15 Jan 2026-6.3%

    Nothing announced by AMPH that day or the session before.

  9. 14 Jan 2026-4.0%

    Nothing announced by AMPH that day or the session before.

  10. 12 Jan 2026+6.0%

Share of unusual movement by asset

For each asset, the share of AMPH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—55%

No dated announcements about its assets since 2 Jul 2024.

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
Beta-2 adrenergic receptorSmall molecule
Asthma
Approved
Beta-2 adrenergic receptorSmall molecule
Asthma
Approved
Glucagon receptor (agonist)Peptide
Diabetes / Hypoglycemia
Severe Hypoglycemia
Approved
Adrenergic receptor (non-selective, alpha+beta) · Alpha-1 and beta-1/beta-2 adrenergic receptors · Adrenergic receptors, nonselectiveSmall molecule
Asthma

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$208M$20M$205M+ $26M short-term inv.—$43M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$184M$22M$224M+ $67M short-term inv.—$51M operating cash flowreport ↗
2026-Q1$171M$27M$171M+ $121M short-term inv.—$48M operating cash flowreport ↗
2025-Q3$192M$22M$217M+ $60M short-term inv.—$53M operating cash flowreport ↗
2025-Q2$174M$20M$188M+ $44M short-term inv.—$36M operating cash flowreport ↗
2025-Q1$171M$20M$183M+ $54M short-term inv.—$35M operating cash flowreport ↗
2024-Q3$191M$21M$192M+ $58M short-term inv.—$60M operating cash flowreport ↗
2024-Q2$182M$18M$190M+ $28M short-term inv.—$69M operating cash flowreport ↗
2024-Q1$172M$17M$201M+ $88M short-term inv.—$55M operating cash flowreport ↗
2023-Q3$181M$17M$271M+ $33M short-term inv.—$64M operating cash flowreport ↗
2023-Q2$146M$17M$151M+ $15M short-term inv.—$55M operating cash flowreport ↗
2023-Q1$140M$20M$177M+ $16M short-term inv.—$40M operating cash flowreport ↗
2022-Q3$120M$19M$157M+ $27M short-term inv.—$20M operating cash flowreport ↗
2022-Q2$123M$23M$166M+ $17M short-term inv.—$2.8M operating cash flowreport ↗
2022-Q1$120M$16M$173M+ $14M short-term inv.—$51M operating cash flowreport ↗
2021-Q3$112M$11M$107M+ $8.0M short-term inv.—$2.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$720M$86M$170M+ $113M short-term inv.—$156M operating cash flowreport ↗

Amphastar Pharmaceuticals reported full-year 2025 revenue of $719.89M, down 1.7% YoY, with R&D spend of $85.84M, up 16.1% YoY, and cash and equivalents of $170.41M. GAAP net income was $98.09M, and operating cash flow for the year was $156.1M.

Management emphasized BAQSIMI's sustained double-digit growth as a top revenue driver and noted FDA approvals of its iron sucrose and teriparatide injections. The pipeline includes one ANDA and one biosimilar insulin candidate filed with the FDA, two biosimilar and two generic products in development, and four recently in-licensed proprietary products spanning oncology, ophthalmology, and immunology, including a fully synthetic corticotropin compound. A legal settlement contributed $23.1M to higher general and administrative expenses, and a $6.0M upfront payment supported a licensing agreement with Nanjing Anji Biotechnology.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$732M$74M$152M+ $70M short-term inv.—$213M operating cash flowreport ↗
2023-FY$644M$74M$145M+ $113M short-term inv.—$184M operating cash flowreport ↗
2022-FY$499M$75M$156M+ $20M short-term inv.—$89M operating cash flowreport ↗
2021-FY$438M$61M$127M+ $10M short-term inv.—$98M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 12 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16PETERS WILLIAM J · director, CFO, EVP & TREASUREROption exercise11,000$17.99$198KForm 4
2026-11-16PETERS WILLIAM J · director, CFO, EVP & TREASUREROpen-market sale11,000$29.99$330KForm 4
2026-11-16PETERS WILLIAM J · director, CFO, EVP & TREASUREROption exercise (derivative)11,000——Form 4
2026-11-05PETERS WILLIAM J · director, CFO, EVP & TREASUREROption exercise11,000$17.99$198KForm 4
2026-11-05PETERS WILLIAM J · director, CFO, EVP & TREASUREROpen-market sale12,631$28.99$366KForm 4
2026-11-05PETERS WILLIAM J · director, CFO, EVP & TREASUREROption exercise (derivative)11,000——Form 4
2026-11-04PETERS WILLIAM J · director, CFO, EVP & TREASUREROption exercise16,000$13.03$208KForm 4
2026-11-04PETERS WILLIAM J · director, CFO, EVP & TREASUREROpen-market sale16,000$28.03$448KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 212 reporting institutions held 32.0M shares ($605.9M).

#InstitutionSharesValue
1BlackRock, Inc.5,421,343$106.2M
2DIMENSIONAL FUND ADVISORS LP2,027,947$39.7M
3STATE STREET CORP1,607,515$31.5M
4VANGUARD CAPITAL MANAGEMENT LLC1,543,655$30.2M
5TD Asset Management Inc1,541,044$30.2M
6FULLER & THALER ASSET MANAGEMENT, INC.1,395,139$27.3M
7MARSHALL WACE, LLP1,025,640$20.1M
8AMERICAN CENTURY COMPANIES INC1,017,538$19.9M
9GEODE CAPITAL MANAGEMENT, LLC976,650$19.1M
10Boston Trust Walden Corp944,789$18.5M
11Epoch Investment Partners, Inc.898,895$17.6M
12VANGUARD PORTFOLIO MANAGEMENT LLC787,816$15.4M
13D. E. Shaw & Co., Inc.665,542$13.0M
14Invesco Ltd.604,774$11.8M
15RENAISSANCE TECHNOLOGIES LLC553,900$10.9M